None listed
Conditions
Interventions
Drug, Genetic : Betaloc tab 100 mg, single dose, oral administration
Sponsors
Kyungpook National University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Healthy male subjects between the ages of 20 and 50 years at screening; 2.Subjects with a body weight within ± 20% of their ideal weight; 3.Subjects must be in generally good health as determined by pre-study medical history and physical examination, with no congenital or chronic diseases; 4.Subjects must be able to read, understand, and willing to decide to participate in the study, follow the study directions and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Hypersensitivity to the study medication or any related medication, including any other constituents of the formulation or past history of allergic reaction; 2.Presence or history of cardiovascular, pulmonary, renal, endocrine, hematologic, gastrointestinal, central nervous system, psychiatric, or malignant disease; 3.Diagnosis of hypotension (systolic 150mmHg or diastolic > 100mmHg)made during the screening period or current diagnosis of hypertension 4.Resting pulse rate of 21 units/week) or subjects who are not willing to abstain from drinking for the duration of study; 6.A history of serious trauma within 4 weeks, or resection operation (excluding simple appendectomy or herniorrhaphy) and/or relevant history or laboratory or clinical findings indicative of acute disease 7.A history of drug abuse. 8.Use of any prescription drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to administration of study drug; 9.Use of any other investigational drug within 3 months prior to administration of study drug; 10.Donation of whole blood within 2 months or any blood products within 1 month, prior to administration of study drug; 11.Excessive smoking (>10 cigarettes/day) 12.Any abnormal diet, likely to influence absorption, distribution, metabolism, and excretion of the drug (e.g. habitually taking more than 1L of grapefruit juice/day within 7 days prior to administration of study drug) 13.Positive test result for hepatitis (B or C) or HIV or VDRL 14.Subject who is not eligible to participate in this study, as judged by an investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC | — |
Countries
Korea, Republic of
Contacts
Public ContactYoung-Ran Yoon
Kyungpook National University Hospital
Outcome results
None listed